HELP
Helus Pharma Inc.Figures below are compared against other companies classified under Pharmaceutical Preparations.
Grades vs. industry
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | Not reported | 70.7% | — |
Operating margin Operating income as a share of revenue. | Not reported | -15.3% | — |
Net margin Net income as a share of revenue. | Not reported | -13.0% | — |
Free cash flow margin Free cash flow as a share of revenue. | Not reported | -2.0% | — |
Return on equity Net income divided by shareholder equity. | -47.7% | -14.2% | 120 / 164 |
Return on assets Net income divided by total assets. | -43.7% | -9.5% | 151 / 188 |
Return on invested capital After-tax operating profit over debt plus equity less cash. | Not reported | -6.1% | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | Not reported | 0.43x | — |
Current ratio Current assets over current liabilities. | 7.75x | 2.96x | 21 / 189 |
Quick ratio Current assets excluding inventory, over current liabilities. | 7.75x | 2.58x | 21 / 189 |
Interest coverage Operating income divided by interest expense. | Not reported | -0.74x | — |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | Not reported | -1.25x | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Insider activity
Trades reported by officers, directors and 10% shareholders on SEC Form 4. 9 of the last 11 reported transactions were open-market purchases; the rest are mostly sales and compensation.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 30, 2026 | Glavine Paul Chief Growth Officer | Grant or award | 248,000 | — | — |
| Sep 30, 2026 | So Eric H. L. Director | Grant or award | 248,000 | — | — |
| Sep 29, 2026 | Cavers Greg Chief Financial Officer | Open-market purchase | 3,000 | $12.91 | $38.7K |
| Sep 21, 2026 | Halstead Michael Chief Executive Officer | Open-market purchase | 100,000 | $13.47 | $1.35M |
| Sep 8, 2026 | Glavine Paul Chief Growth Officer | Open-market purchase | 100,000 | $12.47 | $1.25M |
| Sep 8, 2026 | Glavine Paul Chief Growth Officer | Open-market purchase | 100,000 | $12.47 | $1.25M |
| Sep 8, 2026 | So Eric H. L. Executive Chair | Open-market purchase | 100,000 | $12.39 | $1.24M |
| Sep 4, 2026 | So Eric H. L. Executive Chair | Open-market purchase | 100,000 | $12.09 | $1.21M |
| Sep 3, 2026 | Glavine Paul Chief Growth Officer | Open-market purchase | 100,000 | $11.78 | $1.18M |
| Sep 1, 2026 | So Eric H. L. Executive Chair | Open-market purchase | 95,000 | $11.80 | $1.12M |
| Aug 31, 2026 | Glavine Paul Chief Growth Officer | Open-market purchase | 90,000 | $11.59 | $1.04M |
A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.
Annual financials
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | CAD 0.00 | CAD 864.0K |
| Gross profit | — | — | — | CAD 0.00 | CAD 200.0K |
| Net income | -CAD 113.14M | -CAD 78.08M | -CAD 47.49M | -CAD 67.63M | -CAD 32.22M |
| EPS (diluted) | — | — | -CAD 0.26 | -CAD 0.40 | n/c |
| Operating cash flow | -CAD 101.30M | -CAD 68.91M | -CAD 47.43M | -CAD 45.21M | -CAD 19.03M |
| Capital expenditure | — | CAD 21.0K | CAD 142.0K | CAD 105.0K | CAD 135.0K |
| Free cash flow | — | -CAD 68.93M | -CAD 47.57M | -CAD 45.31M | -CAD 19.16M |
| Total assets | CAD 258.62M | CAD 302.02M | CAD 53.90M | CAD 84.06M | CAD 92.11M |
| Shareholder equity | CAD 237.20M | CAD 291.93M | CAD 48.23M | CAD 76.16M | CAD 86.12M |
| Cash | CAD 135.02M | CAD 208.99M | CAD 16.63M | CAD 53.64M | CAD 64.03M |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
Amounts are in CAD, as the company reports them. Nothing here is converted to dollars, so these figures cannot be compared directly against a company reporting in another currency. Margins, returns and other ratios are unaffected.
n/c marks per-share figures that are not comparable. Companies report each year as their filings stated it, and an annual report restates only its two prior years — so after a stock split, older years remain on the pre-split share count. Totals above are unaffected.
Source
Figures come from Helus Pharma Inc.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 40-F filed Jul 1, 2025. View filings on EDGAR.